Back to today’s briefing

Story perspectives

FDA's Opioid Test Approval Sparks Controversy Over Accuracy

1/29/2025

46 8

Summary

Story summary

The FDA's approval of AvertD, a genetic test aimed at assessing opioid use disorder risk, faces scrutiny as new research reveals it only explains 0.40% of risk variation. In contrast, age and sex factors contribute significantly at 3.27%. Critics warn this could mislead patients and exacerbate the ongoing opioid crisis.

1 of 1

Story summary

The FDA's approval of AvertD, a genetic test aimed at assessing opioid use disorder risk, faces scrutiny as new research reveals it only explains 0.40% of risk variation. In contrast, age and sex factors contribute significantly at 3.27%. Critics warn this could mislead patients and exacerbate the ongoing opioid crisis.